Online inquiry

IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2681MR)

This product GTTS-WQ2681MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Low bone mineral density research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2681MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13614MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ386MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ899MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ2564MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ4613MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ5106MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ2624MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ13476MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW